Literature DB >> 12499177

In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates.

Joseph Meletiadis1, Johan W Mouton, Jacques F G M Meis, Paul E Verweij.   

Abstract

The in vitro interaction between terbinafine and the azoles voriconazole, miconazole, and itraconazole against five clinical Scedosporium prolificans isolates after 48 and 72 h of incubation was tested by a microdilution checkerboard (eight-by-twelve) technique. The antifungal effects of the drugs alone and in combination on the fungal biomass as well as on the metabolic activity of fungi were measured using a spectrophotometric method and two colorimetric methods, based on the lowest drug concentrations showed 75 and 50% growth inhibition (MIC-1 and MIC-2, respectively). The nature and the intensity of the interactions were assessed using a nonparametric approach (fractional inhibitory concentration [FIC] index model) and a fully parametric response surface approach (Greco model) of the Loewe additivity (LA) no-interaction theory as well as a nonparametric (Prichard model) and a semiparametric response surface approaches of the Bliss independence (BI) no-interaction theory. Statistically significant synergy was found between each of the three azoles and terbinafine in all cases, although with different intensities. A 27- to 64-fold and 16- to 90-fold reduction of the geometric mean of the azole and terbinafine MICs, respectively, was observed when they were combined, resulting in FIC indices of <1 to 0.02. Using the MIC-1 higher levels of synergy were obtained, which were more consistent between the two incubation periods than using the MIC-2. The strongest synergy among the azoles was found with miconazole using the BI-based models and with voriconazole using the LA-based models. The synergistic effects both on fungal growth and metabolic activity were more potent after 72 h of incubation. Fully parametric approaches in combination with the modified colorimetric method might prove useful for testing the in vitro interaction of antifungal drugs against filamentous fungi.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12499177      PMCID: PMC149034          DOI: 10.1128/AAC.47.1.106-117.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 2.  A three-dimensional model to analyze drug-drug interactions.

Authors:  M N Prichard; C Shipman
Journal:  Antiviral Res       Date:  1990 Oct-Nov       Impact factor: 5.970

3.  Combination chemotherapy for the treatment of invasive infections by Scedosporium prolificans.

Authors:  J Meletiadis; J W Mouton; J F Meis; P E Verweij
Journal:  Clin Microbiol Infect       Date:  2000-06       Impact factor: 8.067

Review 4.  Antifungal susceptibility testing: technical advances and potential clinical applications.

Authors:  M A Pfaller; J H Rex; M G Rinaldi
Journal:  Clin Infect Dis       Date:  1997-05       Impact factor: 9.079

Review 5.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

6.  In vitro activities of four novel triazoles against Scedosporium spp.

Authors:  A J Carrillo; J Guarro
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

7.  The expected effect of a combination of agents: the general solution.

Authors:  M C Berenbaum
Journal:  J Theor Biol       Date:  1985-06-07       Impact factor: 2.691

8.  Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine.

Authors:  W R Greco; H S Park; Y M Rustum
Journal:  Cancer Res       Date:  1990-09-01       Impact factor: 12.701

Review 9.  Antifungal agents in the 1990s. Current status and future developments.

Authors:  C A Kauffman; P L Carver
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

Review 10.  The triazole antifungal agents: a review of itraconazole and fluconazole.

Authors:  E M Bailey; D J Krakovsky; M J Rybak
Journal:  Pharmacotherapy       Date:  1990       Impact factor: 4.705

View more
  68 in total

1.  Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole.

Authors:  Javier Afeltra; Roxana G Vitale; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

2.  Differences in interactions between azole drugs related to modifications in the 14-alpha sterol demethylase gene (cyp51A) of Aspergillus fumigatus.

Authors:  G Garcia-Effron; E Mellado; A Gomez-Lopez; L Alcazar-Fuoli; M Cuenca-Estrella; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

3.  Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis.

Authors:  Fred Widmer; Lesley C Wright; Daniel Obando; Rosemary Handke; Ranjini Ganendren; David H Ellis; Tania C Sorrell
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  Treatment options in emerging mold infections.

Authors:  Patricia Muñoz; Jesús Guinea; Emilio Bouza
Journal:  Curr Infect Dis Rep       Date:  2008-11       Impact factor: 3.725

5.  In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans.

Authors:  Lingmei Sun; Shujuan Sun; Aixia Cheng; Xiuzhen Wu; Yu Zhang; Hongxiang Lou
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

6.  A Case of Cutaneous Mycosis Caused by Scedosporium dehoogii on an Immunocompromised Patient.

Authors:  Yuichi Sakata; Fumiaki Taga; Tsuyoshi Ushigami; Kiminobu Takeda; Kazushi Anzawa; Akiko Nishibu; Takashi Mochizuki
Journal:  Mycopathologia       Date:  2017-09-01       Impact factor: 2.574

7.  Locally extensive angio-invasive Scedosporium prolificans infection following resection for squamous cell lung carcinoma.

Authors:  Natasha E Holmes; Janine M Trevillyan; Sarah E Kidd; Trishe Y-M Leong
Journal:  Med Mycol Case Rep       Date:  2013-04-19

8.  Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole.

Authors:  Eric Nulens; Cathrien Eggink; Antonius J M M Rijs; Pieter Wesseling; Paul E Verweij
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

Review 9.  Infections caused by Scedosporium spp.

Authors:  Karoll J Cortez; Emmanuel Roilides; Flavio Quiroz-Telles; Joseph Meletiadis; Charalampos Antachopoulos; Tena Knudsen; Wendy Buchanan; Jeffrey Milanovich; Deanna A Sutton; Annette Fothergill; Michael G Rinaldi; Yvonne R Shea; Theoklis Zaoutis; Shyam Kottilil; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

10.  In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Monia Maracci; Annette W Fothergill; Isabella Baldassarri; Michael G Rinaldi; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.